



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

In vitro susceptibility of methicillin-resistant *Staphylococcus aureus* isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid



Johanna Marcela Vanegas Múnera, Ana María Ocampo Ríos, Daniela Montoya Urrego, Judy Natalia Jiménez Quiceno*

Universidad de Antioquia, Escuela de Microbiología, Grupo de Microbiología Básica y Aplicada, Medellín, Colombia

ARTICLE INFO

Article history:

Received 23 November 2016

Accepted 23 March 2017

Available online 19 April 2017

Keywords:

MRSA

Skin and soft tissues infections

Tedizolid

Linezolid

Vancomycin

Daptomycin

ABSTRACT

Introduction: Treatment of multidrug-resistant Gram-positive infections caused by *Staphylococcus aureus* remains as a clinical challenge due to emergence of new resistance mechanisms. Tedizolid is a next-generation oxazolidinone, recently approved for skin and soft tissues infections. We conducted a study to determine *in vitro* susceptibility to vancomycin, daptomycin, linezolid and tedizolid in MRSA clinical isolates from adult patients with skin and soft tissue infections.

Material and methods: Methicillin-resistant *S. aureus* isolates were collected in three tertiary-care hospitals of Medellín, Colombia, from February 2008 to June 2010 as part of a previous study. Clinical characteristics were assessed by medical records and MIC values were determined by Epsilometer test. Genotypic analysis included *spa* typing, MLST, and SCCmec typing.

Results: A total of 150 MRSA isolates were evaluated and tedizolid MIC values obtained showed higher *in vitro* activity than other antimicrobials, with MIC values ranging from 0.13 µg/mL to 0.75 µg/mL and lower values of MIC₅₀ and MIC₉₀ (0.38 µg/mL and 0.5 µg/mL). In contrast, vancomycin and linezolid had higher MIC values, which ranged from 0.5 µg/mL to 2.0 µg/mL and from 0.38 µg/mL to 4.0 µg/mL, respectively. Tedizolid MICs were 2- to 5-fold lower than those of linezolid. Clinical characteristics showed high previous antimicrobial use and hospitalization history. The majority of the strains belong to the CC8 harboring the SCCmec IVc and were associated with the *spa* t1610 (29.33%, n = 44).

Conclusion: *In vitro* effectiveness of tedizolid was superior for isolates from skin and soft tissue infections in comparison with the other antibiotics evaluated. The above added to its less toxicity, good bioavailability, daily dose and unnecessary of dosage adjustment, make tedizolid in a promising alternative for the treatment of infections caused by MRSA.

© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: jnatalia.jimenez@udea.edu.co (J.N. Jiménez Quiceno).

<http://dx.doi.org/10.1016/j.bjid.2017.03.010>

1413-8670/© 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Staphylococcus aureus is one of the most important pathogens in humans, being responsible for various types of infections in the healthcare and community settings.^{1,2} Among of these, skin and soft tissue infections (SSTIs) play an important role, not only by their high frequency but also due to severe forms that affect deep tissues, causing serious implications as high morbidity rates and increased hospital stay and costs.^{1,3}

This microorganism is characterized by its high capacity to adapt to antimicrobials by the acquisition of several resistance mechanisms.^{2–4} Particularly, the emergence of methicillin-resistance isolates (MRSA) has limited therapeutic options, because this resistance involves low affinity for all β -lactam antibiotics.⁵

Vancomycin has been considered an effective option for the treatment of skin and soft tissue infections caused by MRSA. However, the high burden of these infections in hospitals has led to overuse of this antibiotic which in turn has led to increased values of minimum inhibitory concentration (MIC), emergence of intermediate and total resistance to this antimicrobial and increased mortality.^{6–8}

This situation underscores the need for new antimicrobial options to the treatment of infections caused by MRSA which respond to changing resistance patterns.⁸ Currently, the therapeutic options approved by Food and Drug Administration (FDA) for the SSTIs by MRSA include daptomycin, linezolid, and the recently introduced, tedizolid.^{9,10}

Tedizolid is a novel oxazolidinone with high potential of action that is approximately four times more potent than linezolid.^{9,10} Although the mechanism of action is similar to other oxazolidinones, tedizolid has shown more advantages, as lower adverse effects over short courses of therapy and favorable pharmacokinetics.^{9–11} Tedizolid shows an increased activity against species of staphylococci and enterococci, including drug-resistant MRSA and vancomycin- and linezolid-resistant phenotypes.^{9–11}

Constant changes in the epidemiology of infections caused by *S. aureus* reaffirm that this microorganism is a major threat for public health and highlights the need to evaluate therapeutic alternatives that allow for a better prognosis of these infections.

In Colombia, MRSA (both healthcare-associated and community-associated) has become a worrisome clinical problem, with a general frequency of 27%, reaching in some cities up to 50%.¹² This situation brings about new challenges for the treatment of this infections and patient safety.

Therefore, the aim of this study was to determine *in vitro* susceptibility to vancomycin, daptomycin, linezolid and tedizolid of MRSA clinical isolates from patients with skin and soft tissue infections, collected in three tertiary-care hospitals of Medellin, Colombia.

Material and methods

Bacterial isolates

Methicillin-resistant *S. aureus* isolates were collected in three tertiary-care hospitals of Medellin, Colombia, from February

2008 to June 2010, as part of a previous cross-sectional study.^{13–15} Hospitals A and B are hospitals with high level of complexity with 754 and 286 beds, respectively, which provide services in all medical specialties; whereas hospital C is a 140-bed cardiology hospital.

Clinical and epidemiological information

Clinical and epidemiological data were obtained from medical records. Information included demographic aspects, medical history, comorbidities, length of hospital stay and outcomes at discharge. Infections were classified as community-associated (CA-MRSA) or healthcare-associated (HA-MRSA), according to definitions established by the CDC.¹⁶

The research protocol was approved by the Bioethics Committee for human Research at Universidad de Antioquia (CBEIH.SIU-approval No. 0841150).

Strains and antibiotic susceptibility

The identification of *S. aureus* was conducted by standard laboratory methods based on colony morphology in sheep blood agar and phenotyping methods such as catalase and coagulase. Antibiotic susceptibilities of *S. aureus* isolates were assessed in accordance with Clinical Laboratory Standards Institute guidelines (CLSI, 2009) using a VITEK-2[®] instrument (bioMérieux Lyon, France). The Antibiotics evaluated included clindamycin, erythromycin, gentamicin, linezolid, moxifloxacin, oxacillin, rifampin, tetracycline, tigecycline, trimethoprim-sulfamethoxazole and vancomycin.

Evaluation of the susceptibility through Epsilometer test

The MICs to vancomycin, daptomycin, linezolid and tedizolid were determined using the Epsilometer test method (E-test) according to the manufacturer's instructions (Etest[®] bioMérieux and Liofilchem[®] MIC Test Strip). MIC₅₀ and MIC₉₀, that correspond respectively to the 50% and the 90% of strains inhibited by a specific concentration of each antibiotic were obtained. The MIC breakpoints were determined according to the criteria defined by CLSI, 2016 as follows: for vancomycin, values less than or equal to 2 μ g/ml, between 4 and 8 μ g/ml, or greater than or equal to 16 μ g/ml were considered susceptible, intermediate and resistant, respectively; for daptomycin, these values were less than or equal to 1 μ g/ml for susceptibility and higher values were deemed as non-susceptible; for linezolid, values less than or equal to 4 μ g/ml were deemed susceptible and greater than or equal to 8 μ g/ml resistant; finally, for tedizolid, values less than or equal to 0.5 μ g/ml were considered susceptible, 1 μ g/ml intermediate and values higher than or equal to 2 μ g/ml resistant. Strain ATCC 29213 of *S. aureus* was used as a control strain.

Molecular characterization

Presence of the species-specific *nuc* and *femA* genes, as well as the *mecA* gene (determinant of methicillin resistance) were verified by polymerase chain reaction (PCR) as previously

Table 1 – Clinical and epidemiological characteristics among MRSA infections.

Characteristics	Total No (%)	CA-MRSA No (%)	HA-MRSA No (%)	p-Value
Hospital				0.077
Hospital A	91 (60.67)	57 (54.81)	34 (73.91)	
Hospital B	56 (37.33)	45 (43.27)	11 (23.91)	
Hospital C	3 (2.00)	2 (1.92)	1 (2.17)	
Year of MRSA isolation				0.825
2008	61 (40.67)	44 (42.31)	17 (36.96)	
2009	64 (42.67)	43 (41.35)	21 (45.65)	
2010	25 (16.67)	17 (16.35)	8 (17.39)	
Gender				0.938
Male	92 (61.33)	64 (61.54)	28 (60.87)	
Female	58 (38.67)	40 (38.46)	18 (39.13)	
Age (years)				0.110
Median (RIQ)	48 (29–64)	48.5 (31.5–65.0)	42 (25–57)	
Hospital stay (days)				0.003
Median (RIQ)	19 (9–36)	16 (8–34)	28 (17–48)	
Comorbidities				0.899
Diabetes mellitus	49 (32.67)	36 (34.62)	13 (28.26)	0.444
Atopy	7 (4.67)	3 (2.88)	4 (8.70)	0.120
Neoplasia	13 (8.67)	10 (9.62)	3 (6.52)	0.535
Immunosuppression	25 (16.67)	15 (14.42)	10 (21.74)	0.268
Chronic renal disease	21 (14.0)	18 (17.31)	3 (6.52)	0.079
Trauma in past 6 months	39 (26.0)	25 (24.04)	14 (30.43)	0.410
History in the past year of:				
Hospitalization	84 (56.00)	66 (63.46)	18 (39.13)	0.006
Surgery	46 (30.67)	33 (31.73)	13 (28.26)	0.671
Dialysis	7 (4.67)	6 (5.77)	1 (2.17)	0.336
Stay in ICU	6 (4.0)	3 (2.88)	3 (6.0)	0.295
Stay in burns unit	2 (1.33)	1 (0.96)	1 (2.17)	0.551
Stay in the past year in home nursing	5 (3.33)	4 (3.85)	1 (2.17)	0.599
Antimicrobial use in past 6 months	73 (51.41)	49 (50.52)	24 (53.33)	0.755
Invasive medical devices	58 (38.67)	40 (38.46)	18 (39.13)	0.938
Central venous catheter	13 (8.67)	9 (8.65)	4 (8.70)	0.993
Probes	26 (17.33)	16 (15.38)	10 (21.74)	0.343
Osteosynthesis material	15 (16.0)	10 (9.62)	5 (10.87)	0.813
Outcome				0.010
Cure	139 (92.67)	100 (97.09)	39 (86.67)	
Death	9 (6.0)	3 (2.91)	6 (13.33)	

described.^{17,18} Genes encoding staphylococcal enterotoxins (*sea*, *seb*, *sec*, *sed*, *see*), toxic shock syndrome toxin 1 (*tst*), and exfoliative toxins A and B (*eta*, *etb*) were detected by multiplex PCR. The *lukS/F-PV* genes encoding Pantone-Valentine leukocidin (PVL), as well as the *arcA* gene from the USA300-associated arginine catabolic mobile element (ACME), were also assayed.^{18,19} Strain typing was performed using protein A typing (*spa*), multilocus sequence typing (MLST), and SCCmec typing.^{20–23}

Statistical analyses

Comparisons of clinical characteristics were carried out between CA-MRSA- and HA-MRSA-infected patients after applying CDC criteria. Categorical variables were compared using chi-square test or Fisher's exact test and Mann-Whitney *U* tests for continuous variables. *p*-Values ≤ 0.05 were considered statistically significant. Statistical analyses were performed using the software package Stata® v14.0.

Results

A total of 150 MRSA isolates from adult patients with skin and soft tissue infections were evaluated. The demographic and clinical characteristics of patients are summarized in Table 1. The majority of patients were male (61.33%, *n* = 92), with an age range between 15 and 89 years old and hospitalized in hospital A (60.67%, *n* = 91).

Above 69% of infections were classified as community-associated according to CDC criteria after individual assessment of cases; the medical histories revealed frequent use of antibiotics (51.41%, *n* = 73), comorbidities mainly diabetes mellitus (32.67%, *n* = 49), and history in the past year of hospitalization and surgery (56%, *n* = 84 and 30.67%, *n* = 46, respectively). The most frequent outcome was cure (92.67%, *n* = 139).

When comparing clinical characteristics among MRSA infections (CA-MRSA and HA-MRSA), three variables showed statistically significant differences: hospital stay (*p* = 0.003),

Table 2 – SCCmec types among to CA-MRSA and HA-MRSA isolates.

SCCmec type	Total No (%)	CA-MRSA No (%)	HA-MRSA No (%)
SCCmec I	43 (0.67)	21 (20.19)	22 (47.83)
SCCmec II	1 (28.67)	1 (0.96)	0
SCCmec III	0 (0.67)	0	0
SCCmec IV	5 (3.33)	3 (2.88)	2 (4.35)
SCCmec IVa	5 (3.33)	5 (4.81)	0
SCCmec IVc	95 (63.33)	73 (70.19)	22 (47.83)
Non typable	1 (0.67)	1 (0.96)	0

history of hospitalization ($p=0.06$) and outcome ($p=0.010$). Length of hospital stay was longer for patients with HA-MRSA infections, while previous hospitalization had a major tendency among CA-MRSA infections. The outcome death was more frequent among HA-MRSA group.

Molecular characterization of isolates

The presence of *nuc*, *femA* and *mecA* genes were confirmed in all isolates. The most common clonal complex was CC8 (63.3%, $n=95$), followed by CC5 (31.3%, $n=47$). Furthermore, CC45 (1.3%), CC1 (0.7%) and CC30 (0.7%) were detected in low frequency.

Regarding typing of chromosome cassette *mec* (SCCmec), a high percent of isolates classified as CA-MRSA and HA-MRSA harbored SCCmec type IVc ($n=73$, 70.19% and $n=22$, 47.83%, respectively), followed by SCCmec type I ($n=21$, 20.19% and $n=22$, 47.83%, respectively). The remaining SCCmec types were present at very low frequency (Table 2).

Typing of chromosome cassette *mec* according to tedizolid MIC showed that the most common was the SCCmec type IVc (63.3%, $n=95$) for all isolates, independently to tedizolid MIC, followed by the SCCmec type I (28.7%, $n=43$) (Fig. 1).

Several types of the protein A were found: t1610 (30.67%, $n=46$), t149 (16.67%, $n=25$), t008 (11.33%, $n=17$), and others as t024 (10%, $n=15$), t1311 (4%, $n=6$) and t7279 (4%, $n=6$).

The strains carrying the SCCmec type I belonged to the *spa* t149 and CC5. While the strains carrying SCCmec IVc belonged to *spa* types t1610, t008, and t024 of the CC8.

CC8 MRSA strains harboring SCCmec type IVc and belonged to the *spa* t1610 were more frequent (29.33%, $n=44$) and




Fig. 1 – SCCmec types according to tedizolid MIC values in MRSA isolates.

presented MICs values for tedizolid between 0.38 µg/mL and 0.50 µg/mL.

Regarding to virulence factors, the most common gene was *lukS/F-PV* (85.8%, $n=97$), followed by enterotoxin B (18.6%, $n=21$), toxic shock syndrome toxin (17.7%, $n=20$) and enterotoxin D (8.8%, $n=10$) genes. Enterotoxin A, C and E were found in only three isolates (0.9%).

Antimicrobial susceptibility

Among the total of MRSA isolates, 43.33% ($n=65$) and 35.33% ($n=53$) were resistant to tetracycline and erythromycin, respectively. Resistance to clindamycin, gentamicin, moxifloxacin and rifampin, was less than 21%.

The MIC values obtained through E-test showed susceptibility to vancomycin, daptomycin, linezolid and tedizolid, except for one isolate with MIC=1.5 µg/mL to daptomycin (Table 3). Tedizolid was more active than other antimicrobials, with MIC values ranging from 0.13 µg/mL to 0.75 µg/mL, and lower values of MIC₅₀ and MIC₉₀ (0.38 and 0.5, respectively). In contrast, vancomycin and linezolid had high MICs with values even above 1.5 µg/mL (Table 3, Fig. 2).

Most isolates showed a tedizolid MIC of 0.38 µg/mL (38%, $n=57$) and a linezolid MIC of 2 µg/mL (36%, $n=55$). Interestingly, 18.7% ($n=28$) and 2% ($n=3$) of the isolates, presented MICs values of 3 µg/mL and 4 µg/mL to linezolid, respectively. Additionally, tedizolid MICs values were 3- to 5-fold lower than those of linezolid (Fig. 2).

The MICs values for the *S. aureus* ATCC 29213 control strain, falling within the range for the quality control recommended by CLSI (0.5–2 µg/mL for vancomycin, 0.12–1 µg/mL for daptomycin, 0.5–2 µg/mL for linezolid, and 0.25–1 µg/mL for tedizolid).

Discussion


Tedizolid has been recently approved by the FDA for treatment of skin and soft tissue infections caused by Gram-positive bacteria, including MRSA.¹¹ The importance of this antimicrobial is focused on the emergence of less susceptible or resistant MRSA strains to vancomycin (hVISA and VISA) and the discovery of a possible dissemination of *cfrr* gene, that is horizontally transferable and confers resistance to linezolid.²⁴

The results of this study evidenced that tedizolid was the most effective antibiotic compared with vancomycin, daptomycin and linezolid, showing lower MIC values although its resistance breakpoint is considerably lower than the other antimicrobials and being consistent with conclusions in other studies.²⁵ This can be better appreciated with MIC₅₀ and MIC₉₀ values, that points to the effectiveness of the antibiotic and the behavior of susceptibility of MRSA isolates. MIC₉₀ display important differences between the four antibiotics tested. Tedizolid was notably superior, with MIC₉₀ values below 0.5 µg/mL, while the MIC₉₀ values were 1 µg/mL, 1.5 µg/mL, and 3 µg/mL for daptomycin, vancomycin and linezolid, respectively.

Greater activity and a narrow range of tedizolid MICs (between 0.19 and 0.75 µg/mL) has been reported in several studies across a variety of culture conditions and with

Table 3 – Frequency of occurrence and cumulative percent distribution of MICs for selected drugs against *S. aureus* isolates.

Antimicrobials	No. (cumulative %) of isolates inhibited at MIC ($\mu\text{g/ml}$) of:											MIC ₅₀	MIC ₉₀	% Susceptible	% Resistant	
	≤ 0.19	0.25	0.38	0.5	0.75	1	1.5	2	3	4	>4					
Daptomycin	0 (0)	3 (2.0)	31 (22.7)	46 (53.4)	46 (84.1)	23 (99.4)	1 (100)	0	0	0	0	0	0.5	1	100	0
Vancomycin	0 (0)	0 (0)	0 (0)	5 (3.3)	30 (23.3)	76 (74.0)	36 (98.0)	3 (100)	0	0	0	0	1	1.5	100	0
Linezolid	0 (0)	0 (0)	1 (0.7)	1 (1.4)	5 (4.7)	18 (16.7)	39 (42.7)	55 (79.4)	28 (98.1)	3 (100)	0	0	2	3	100	0
Tedizolid	12 (8)	34 (30.7)	57 (68.7)	41 (96)	6 (100)	0	0	0	0	0	0	0	0.38	0.5	100	0

**Fig. 2 – Comparison between tedizolid, daptomycin, vancomycin and linezolid MIC in MRSA isolates.**

reference and clinical isolates of *S. aureus*.²⁶ A study carried out in South Korea reported a tedizolid MIC₉₀ of 0.5 $\mu\text{g/ml}$ in Gram-positive isolates as MRSA, vancomycin-resistant enterococci, *S. pneumoniae*, *S. pyogenes*, *S. agalactiae* and *Clostridium* spp. and showed more potency of tedizolid than linezolid or vancomycin.²⁷ Similarly, a survey study of 1063 Gram-positive and Gram-negative isolates from United States, Great Britain, France, Germany, and Australia revealed that tedizolid was 4–8 fold more potent against staphylococci than linezolid, with a MIC₉₀ of 0.5 $\mu\text{g/ml}$, and 2–8 fold more potent than vancomycin against these microorganisms.²⁸ More recent studies have confirmed these results, which have shown tedizolid MICs 4–32 fold lower than those of linezolid in clinical isolates of linezolid-resistant staphylococci and enterococci,²⁹ maintaining activity against isolates with reduced susceptibility to alternative agents such as vancomycin and daptomycin.^{25,30,31}

Tedizolid and linezolid are both oxazolidinones and share many characteristics such as activity against Gram-positive bacteria, the same mechanism of action and high oral bioavailability. However, tedizolid has shown better *in vitro* activity compared to linezolid, as it can bind to additional targets sites in 23s rRNA which leads to activity against MRSA strains with linezolid resistance mediated by *cfr* gene mutation.³² Additionally, tedizolid is approximately 90% protein-bound and has a half-life near two-fold greater than linezolid, leading to only six days of therapy (tedizolid 200 mg once daily for six days vs linezolid 600 mg twice daily for 10 days) and not requiring dosage adjustment in patients with any renal or hepatic dysfunction.^{33–35} Furthermore, the toxicity and *in vitro* tedizolid resistance rates are lower than for other antimicrobials.^{36,37}

In present study, high MICs values were observed for vancomycin and daptomycin, being beyond or in the upper limit of susceptibility. Most clinicians use vancomycin for empiric and definitive therapy for MRSA infections; however, recent reports have drawn attention to increased treatment failures at MIC 1 $\mu\text{g/ml}$, although CLSI breakpoint defines the upper limit of susceptibility in 2 $\mu\text{g/ml}$.⁸ Besides, clinical outcomes with vancomycin depend of bacterial load at site of infection, and higher rates of nephrotoxicity are associated with high-dose therapy.³⁸

Daptomycin is an alternative to vancomycin for patients with MRSA infections, but some authors have recommended to use high doses to minimize the emergence of elevated MIC values, which has been associated with an increase in the vancomycin MIC and the heteroresistant phenotype (hVISA).^{39,40}

Interestingly, in this study the activity of tedizolid was maintained in strains isolated from patients with different characteristics including an age range between 15 and 89 years old, different comorbidities and previous antimicrobial

use. Likewise, the MIC values for tedizolid was similar in all isolates and the results were consistent in both community and health care-associated infections.

On the other hand, the most frequent genotype was CC8-t1610-SCCmecIVc, which is common in community-associated strains with Panton-Valentine leucocidin, against which tedizolid retained activity, too.⁴¹ These community-associated strains are being introduced to hospitals, replacing healthcare-associated strains, according to previous studies from Medellín.⁴²

Efficacy, safety, and tolerability of tedizolid have been evaluated in Latino patients and tedizolid had presented comparable efficacy to linezolid, sustained clinical success rates, and lower abnormal platelet counts and gastrointestinal events, without warranting dose adjustment.⁴³ Countries like Colombia, where MRSA has become a worrisome clinical problem, with a general frequency of 27%, reaching up to 50% in some cities,¹² increased resistance rates and high antibiotic pressure generate additional cost to health system. Therapeutic alternatives like tedizolid are thus necessary to improve prognosis of infections caused by Gram-positive bacteria such as *S. aureus*.⁴⁴

In conclusion, *in vitro* effectiveness of tedizolid was superior for isolates from skin and soft tissue infections in comparison with other therapy alternatives like vancomycin, daptomycin and even linezolid. The combination of less toxicity, good bioavailability, once daily dose and no requiring dosage adjustment makes tedizolid a promising alternative for the treatment of infections caused by *S. aureus*, including methicillin-resistant isolates.

Funding

This work was supported by BAYER S.A.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

- DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in *Staphylococcus aureus* infections. *Infect Dis Clin N Am*. 2009;23:17–34.
- Aires de Sousa M, de Lencastre H. Bridges from hospitals to the laboratory: genetic portraits of methicillin-resistant *Staphylococcus aureus* clones. *FEMS Immunol Med Microbiol*. 2004;40:101–11.
- Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant *Staphylococcus aureus* infection. *Clin Infect Dis*. 2008;46 Suppl. 5:S350–9.
- Lowy FD. Antimicrobial resistance: the example of *Staphylococcus aureus*. *J Clin Invest*. 2003;111:1265–73.
- Ruef C. Epidemiology and clinical impact of glycopeptide resistance in *Staphylococcus aureus*. *Infection*. 2004;32:315–27.
- Conly JM, Johnston BL. VISA, hetero-VISA and VRSA: the end of the vancomycin era? *Can J Infect Dis*. 2002;13:282–4.
- Chopra I. Antibiotic resistance in *Staphylococcus aureus*: concerns, causes and cures. *Expert Rev Anti Infect Ther*. 2003;1:45–55.
- van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in *Staphylococcus aureus* infections: a systematic review and meta-analysis. *Clin Infect Dis*. 2012;54:755–71.
- Chan LC, Basuino L, Dip EC, Chambers HF. Comparative efficacy of tedizolid phosphate (prodrug of tedizolid), vancomycin and daptomycin in a rabbit model of methicillin-resistant *Staphylococcus aureus* Endocarditis. *Antimicrob Agents Chemother*. 2015.
- Zhanel GG, Love R, Adam H, et al. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. *Drugs*. 2015;75:253–70.
- Rybak JM, Roberts K. Tedizolid phosphate: a next-generation oxazolidinone. *Infect Dis Ther*. 2015.
- Villalobos AP, Barrero LI, Rivera SM, Ovalle MV, Valera D. Surveillance of healthcare associated infections, bacterial resistance and antibiotic consumption in high-complexity hospitals in Colombia, 2011. *Biomedica*. 2014;34 Suppl. 1:67–80.
- Jimenez JN, Ocampo AM, Vanegas JM, et al. Characterisation of virulence genes in methicillin susceptible and resistant *Staphylococcus aureus* isolates from a paediatric population in a university hospital of Medellín, Colombia. *Mem Inst Oswaldo Cruz*. 2011;106:980–5.
- Jimenez JN, Ocampo AM, Vanegas JM, et al. CC8 MRSA strains harboring SCCmec type IVc are predominant in Colombian hospitals. *PLoS ONE*. 2012;7:e38576.
- Jiménez JN, Ocampo AM, Vanegas JM, et al. A comparison of methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* reveals no clinical and epidemiological but molecular differences. *Int J Med Microbiol*. 2013;303:76–83.
- Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control*. 2008;36:309–32.
- Brakstad OG, Maeland JA. Direct identification of *Staphylococcus aureus* in blood cultures by detection of the gene encoding the thermostable nuclease or the gene product. *APMIS*. 1995;103:209–18.
- Mehrotra M, Wang G, Johnson WM. Multiplex PCR for detection of genes for *Staphylococcus aureus* enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance. *J Clin Microbiol*. 2000;38:1032–5.
- McClure JA, Conly JM, Lau V, et al. Novel multiplex PCR assay for detection of the staphylococcal virulence marker Panton-Valentine leukocidin genes and simultaneous discrimination of methicillin-susceptible from -resistant staphylococci. *J Clin Microbiol*. 2006;44:1141–4.
- Kondo Y, Ito T, Ma XX, et al. Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions. *Antimicrob Agents Chemother*. 2007;51:264–74.
- Shopsin B, Gomez M, Montgomery SO, et al. Evaluation of protein A gene polymorphic region DNA sequencing for typing of *Staphylococcus aureus* strains. *J Clin Microbiol*. 1999;37:3556–63.
- Mulvey MR, Chui L, Ismail J, et al. Development of a Canadian standardized protocol for subtyping methicillin-resistant *Staphylococcus aureus* using pulsed-field gel electrophoresis. *J Clin Microbiol*. 2001;39:3481–5.
- Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *J Clin Microbiol*. 2000;38:1008–15.
- de Dios Caballero J, Pastor MD, Vindel A, et al. Emergence of cfr-mediated linezolid resistance in a methicillin-resistant

- Staphylococcus aureus* epidemic clone isolated from patients with cystic fibrosis. *Antimicrob Agents Chemother.* 2015;60:1878–82.
25. Barber KE, Smith JR, Raut A, Rybak MJ. Evaluation of tedizolid against *Staphylococcus aureus* and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. *J Antimicrob Chemother.* 2016;71:152–5.
 26. Locke JB, Zurenko GE, Shaw KJ, Bartizal K. Tedizolid for the management of human infections: in vitro characteristics. *Clin Infect Dis.* 2014;58 Suppl. 1:S35–42.
 27. Yum JH, Choi SH, Yong D, et al. Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. *Antimicrob Agents Chemother.* 2010;54:5381–6.
 28. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. *Antimicrob Agents Chemother.* 2009;53:3236–9.
 29. Silva-Del Toro SL, Greenwood-Quaintance KE, Patel R. In vitro activity of tedizolid against linezolid-resistant staphylococci and enterococci. *Diagn Microbiol Infect Dis.* 2016;85:102–4.
 30. Lee Y, Hong SK, Choi S, Im W, Yong D, Lee K. In vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study. *Ann Lab Med.* 2015;35:523–30.
 31. Riedel S, Neoh KM, Eisinger SW, Dam LM, Tekle T, Carroll KC. Comparison of commercial antimicrobial susceptibility test methods for testing of *Staphylococcus aureus* and Enterococci against vancomycin, daptomycin, and linezolid. *J Clin Microbiol.* 2014;52:2216–22.
 32. Durkin MJ, Corey GR. New developments in the management of severe skin and deep skin structure infections – focus on tedizolid. *Ther Clin Risk Manag.* 2015;11:857–62.
 33. Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. *Antimicrob Agents Chemother.* 2015;59:864–71.
 34. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis.* 2014;14:696–705.
 35. Hall RG, Michaels HN. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections. *Infect Drug Resist.* 2015;8:75–82.
 36. Flanagan S, Passarell J, Lu Q, Fiedler-Kelly J, Ludwig E, Prokocimer P. Tedizolid population pharmacokinetics, exposure response, and target attainment. *Antimicrob Agents Chemother.* 2014;58:6462–70.
 37. Kisgen JJ, Mansour H, Unger NR, Childs LM. Tedizolid: a new oxazolidinone antimicrobial. *Am J Health Syst Pharm.* 2014;71:621–33.
 38. Rodvold KA, McConeghy KW. Methicillin-resistant *Staphylococcus aureus* therapy: past, present, and future. *Clin Infect Dis.* 2014;58 Suppl. 1:S20–7.
 39. Gould IM, David MZ, Esposito S, et al. New insights into methicillin-resistant *Staphylococcus aureus* (MRSA) pathogenesis, treatment and resistance. *Int J Antimicrob Agents.* 2012;39:96–104.
 40. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in *Staphylococcus aureus*: facts and assumptions. *Lancet Infect Dis.* 2009;9:617–24.
 41. Mariem BJ, Ito T, Zhang M, et al. Molecular characterization of methicillin-resistant Panton-valentine leukocidin positive *Staphylococcus aureus* clones disseminating in Tunisian hospitals and in the community. *BMC Microbiol.* 2013;13:2.
 42. Jiménez JN, Ocampo AM, Vanegas JM, et al. CC8 MRSA strains harboring SCCmec type IVc are predominant in Colombian hospitals. *PLoS ONE.* 2012;7:e38576.
 43. Ortiz-Covarrubias A, Fang E, Prokocimer PG, et al. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections. *Braz J Infect Dis.* 2016;20:184–92.
 44. Barrero LI, Castillo JS, Leal AL, et al. Economic burden of methicillin-resistant *Staphylococcus aureus* bacteremia in critical care patients in hospitals in Bogotá. *Biomedica.* 2014;34:345–53.